EANS-News

Semperit AG Holding / Semperit and Sri Trang sign an agreement on the demerger of the joint venture Siam Sempermed - Seite 2

USD 167.5 million (approx. EUR 157 million) before taxes. Immediately
prior to closing, SSC will declare a dividend equivalent to around
USD 118.2 million and SAC a dividend equivalent to USD 30 million.
From SSC's dividend Semperit will receive around USD 51 million
(approx. EUR 48 million) before taxes in cash, the rest of Semperit's
share of SSC's dividend will be set-off as part of the overall
transaction.

Semperit: full focus on its own growth Semperit CEO Thomas Fahnemann:
"The present agreement is fair for both parties. After the settlement
of the legal disputes, we can fully focus on the development of our
own business. We will continue our growth path in both the Industrial
and Medical Sectors with full power. With the cash inflow, we will
continue to strengthen our capital basis and to advance our
investments."

Veit Sorger, Chairman of the Semperit Supervisory Board: "Semperit
would have wanted to continue the joint venture Siam Sempermed.
However, due to the experiences with the joint venture during the
past years, the agreement reached now is the right step for Semperit.
We would like to successfully continue the reduced cooperation in the
Semperflex segment."

Closing expected for March 2017 The transaction is subject to the
approval of the Supervisory Board of Semperit, a corresponding
resolution passed at the Extraordinary General Meeting of Sri Trang
as well as closing conditions. The closing of the transaction is
expected for March 2017.

In case of a successful closing, all pending arbitration and civil
proceedings between the Semperit Group on the one hand and the Sri
Trang Group and SSC on the other hand will be settled by mutual
consent. Common break-up fees were agreed in case of failure.

From today's point of view, a successful closing of the transaction
would lead to positive special effects in Semperit's Group results
amounting to around EUR 100 to 115 million in the financial year of
2017. This is up against negative special effects in the Group's
result of 2016 amounting to around EUR 30 to 40 million mainly due to
non-cash value adjustments and deferred taxes. These adjustments will
be necessary relating to the planned termination of the joint venture
combined with the development in the Sempermed segment, which is
weaker than expected. Due to these expected special effects, the
existing dividend policy of Semperit has to be evaluated for the
years 2016 and 2017.

Sempermed: strong brand and modern production Even after the
separation, Semperit remains one of the top ten players in the global
market for examination and protective gloves with the Sempermed
segment. Sempermed is one of the leading global glove brands and has